Urocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle

Article English OPEN
Roustit, M. M. ; Vaughan, J. M. ; Jamieson, Pauline ; Cleasby, M E (2014)
  • Publisher: Bioscientifica Ltd
  • Journal: (issn: 0022-0795, vol: 223, pp: 143-154)
  • Related identifiers: doi: 10.1530/JOE-14-0181, pmc: PMC4191181
  • Subject: glucose disposal | urocortin 3 | AMPK | PI3K signalling | skeletal muscle | Research | GLUT4

Insulin resistance (IR) in skeletal muscle is an important component of both type 2 diabetes and the syndrome of sarcopaenic obesity, for which there are no effective therapies. Urocortins (UCNs) are not only well established as neuropeptides but also have their roles in metabolism in peripheral tissues. We have shown recently that global overexpression of UCN3 resulted in muscular hypertrophy and resistance to the adverse metabolic effects of a high-fat diet. Herein, we aimed to establish whether short-term local UCN3 expression could enhance glucose disposal and insulin signalling in skeletal muscle. UCN3 was found to be expressed in right tibialis cranialis and extensor digitorum longus muscles of rats by in vivo electrotransfer and the effects studied vs the contralateral muscles after 1 week. No increase in muscle mass was detected, but test muscles showed 19% larger muscle fibre diameter (P=0.030), associated with increased IGF1 and IGF1 receptor mRNA and increased SER256 phosphorylation of forkhead transcription factor. Glucose clearance into the test muscles after an intraperitoneal glucose load was increased by 23% (P=0.018) per unit mass, associated with increased GLUT1 (34% increase; P=0.026) and GLUT4 (48% increase; P=0.0009) proteins, and significantly increased phosphorylation of insulin receptor substrate-1, AKT, AKT substrate of 160 kDa, glycogen synthase kinase-3β, AMP-activated protein kinase and its substrate acetyl coA carboxylase. Thus, UCN3 expression enhances glucose disposal and signalling in muscle by an autocrine/paracrine mechanism that is separate from its pro-hypertrophic effects, implying that such a manipulation may have promised for the treatment of IR syndromes including sarcopaenic obesity.
  • References (32)
    32 references, page 1 of 4

    Abo T, Iida RH, Kaneko S, Suga T, Yamada H, Hamada Y & Yamane A 2012 IGF and myostatin pathways are respectively induced during the earlier and the later stages of skeletal muscle hypertrophy induced by clenbuterol, a b(2)-adrenergic agonist. Cell Biochemistry and Function 30 671-676. (doi:10.1002/cbf.2848)

    Anderson SB, Goldberg AL & Whitman M 2008 Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. Journal of Biological Chemistry 283 7027-7035. (doi:10.1074/jbc.M706678200)

    Baehr LM, Tunzi M & Bodine SC 2014 Muscle hypertrophy is associated with increases in proteasome activity that is independent of MuRF1 and MAFbx expression. Frontiers in Physiology 5 69. (doi:10.3389/fphys.2014.00069)

    Bale TL, Anderson KR, Roberts AJ, Lee KF, Nagy TR & Vale WW 2003 Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 144 2580-2587. (doi:10.1210/en.2002-0091)

    Bassil MS & Gougeon R 2013 Muscle protein anabolism in type 2 diabetes. Current Opinion in Clinical Nutrition and Metabolic Care 16 83-88. (doi:10.1097/MCO.0b013e32835a88ee)

    Brar BK, Stephanou A, Knight R & Latchman DS 2002 Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. Journal of Molecular and Cellular Cardiology 34 483-492. (doi:10.1006/jmcc.2002.1529)

    Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjos OD, Latchman DS, Lee KF & Vale W 2004 Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145 24-35 discussion 21-23. (doi:10.1210/en.2003-0689)

    Carlin KM, Vale WW & Bale TL 2006 Vital functions of corticotropinreleasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. PNAS 103 3462-3467. (doi:10.1073/pnas. 0511320103)

    Chan TM & Exton JH 1976 A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Analytical Biochemistry 71 96-105. (doi:10.1016/ 0003-2697(76)90014-2) Stephanou AA,KniUghtRD, THsuSY, HHsueh AJ O&LatcRhman DS 20C05

    Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochemical and Biophysical Research Communications 328 442-448. (doi:10.1016/j.bbrc.2005.01.001)

  • Similar Research Results (4)
  • Metrics
    No metrics available
Share - Bookmark